Why the study?
Do antihypertensive drug combinations, such as furosemide and amlodipine, safely control systolic blood pressure in patients with chronic kidney disease?
Do antihypertensive drug combinations, such as furosemide and amlodipine, safely control systolic blood pressure in patients with chronic kidney disease?
In a small observational cohort of CKD patients, the combination of furosemide and amlodipine was commonly prescribed, safe, and effective for controlling systolic blood pressure.
Hypertension is common in hemodialysis patients and can often be difficult to control. Considering the high cardiovascular burden in hemodialysis patients, control of blood pressure is important to improve outcomes. This study is conducted to assess the anti hypertensive drugs treatment in chronic kidney disease (CKD) patients. This is a prospective observational study and includes information regarding CKD patients with co-morbidities like T2DM and HTN and it is conducted among 15 patients which were of both males and females of above 20 yrs of age upto 80 yrs. For these 15 patients e GFR is calculated and stage of severity of CKD was found. Patients with T2DM and Hypertensive are mostly diagnosed with CKD. Loop diuretic (Furosemide)+ calcium channel blocker (Amlodipine) this combination is prescribed more which is found to be safe for CKD patients as for this combination dosage adjustment is not required. In our study among 15 CKD patients 7 dialysis patients were included, majority of the patients have controlled SBP with the antihypertensive combinations.
No takes yet. Share an insight, caveat, or question.
Devi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: